Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00023985

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00023985. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Vaccination With Autologous Tumor Lysate-Pulsed Dendritic Cells - Phase I

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have non-small cell lung cancer.

Study identification

NCT ID: NCT00023985
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Roswell Park Cancer Institute; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Lung Cancer

Interventions

autologous tumor cell vaccine Biological
therapeutic autologous dendritic cells Biological
conventional surgery Procedure

Biological · Procedure

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2001 (Type not available)
Primary completion: Jul 2003 (Actual)
Completion: Aug 2003 (Actual)
Last update posted: Mar 7, 2011

2001 – 2003

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Roswell Park Cancer Institute	Buffalo	New York	14263-0001	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00023985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 7, 2011 · Synced Nov 13, 2026